{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:46:29Z","timestamp":1790343989682,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1016\/j.amjmed.2010.05.007","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T04:47:25Z","timestamp":1285822045000},"page":"111-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Implications of the CHA2DS2-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation"],"prefix":"10.1016","volume":"124","author":[{"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2010.05.007_bib1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1160\/TH07-08-0508","article-title":"Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data","volume":"99","author":"Hughes","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2010.05.007_bib2","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2010.05.007_bib3","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.amjmed.2009.12.013","article-title":"Improving stroke risk stratification in atrial fibrillation","volume":"123","author":"Lip","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2010.05.007_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.amjmed.2010.05.007_bib5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.thromres.2008.09.016","article-title":"Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control","volume":"124","author":"Morgan","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.amjmed.2010.05.007_bib6","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2010.05.007_bib7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1160\/TH08-11-0730","article-title":"Bleeding with anticoagulation therapy\u2014who is at risk, and how best to identify such patients","volume":"102","author":"Palareti","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2010.05.007_bib8","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1161\/01.STR.0000141933.75462.c2","article-title":"Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients","volume":"35","author":"Shireman","year":"2004","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2010.05.007_bib9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2010.05.007_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(98)00198-3","article-title":"Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin","volume":"105","author":"Beyth","year":"1998","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2010.05.007_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/archinte.159.5.457","article-title":"Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism","volume":"159","author":"Kuijer","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2010.05.007_bib12","doi-asserted-by":"crossref","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: the Euro Heart Survey","author":"Pisters","year":"2010","journal-title":"Chest"},{"issue":"103","key":"10.1016\/j.amjmed.2010.05.007_bib13","first-page":"683","article-title":"Anticoagulation therapy and the risk of stroke in patients with Atrial Fibrillation at 'moderate risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice","volume":"4","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjmed.2010.05.007_bib14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1161\/01.STR.0000198839.61112.ee","article-title":"Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial","volume":"37","author":"Sato","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.amjmed.2010.05.007_bib15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjmed.2010.05.007_bib16","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1052-3057(10)80159-4","article-title":"A differential effect of aspirin in prevention of stroke on atrial fibrillation","volume":"3","year":"1993","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.amjmed.2010.05.007_bib17","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.amjmed.2010.05.007_bib18","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934310004523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934310004523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:55:02Z","timestamp":1757580902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934310004523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0002934310004523"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2010.05.007","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implications of the CHA2DS2-VASc and HAS-BLED Scores for Thromboprophylaxis in Atrial Fibrillation","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2010.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}